<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26455353</article-id>
<article-id pub-id-type="pmc">4742288</article-id>
<article-id pub-id-type="doi">10.1111/bph.13364</article-id>
<article-id pub-id-type="publisher-id">BPH13364</article-id>
<article-id pub-id-type="other">2015-BJP-0809-RCT-G.R1</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Themed Section: Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Microglial activation and progressive brain changes in schizophrenia</article-title>
<alt-title alt-title-type="right-running-head">Microglial activation and brain changes in schizophrenia</alt-title>
<alt-title alt-title-type="left-running-head">L E Laskaris et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="editor" id="bph13364-cr-0001">
<name>
<surname>Stewart</surname>
<given-names>AG</given-names>
</name>
</contrib>
<contrib contrib-type="editor" id="bph13364-cr-0002">
<name>
<surname>Beart</surname>
<given-names>PM</given-names>
</name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="bph13364-cr-0003">
<name>
<surname>Laskaris</surname>
<given-names>L E</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8258-8925</contrib-id>
<xref ref-type="aff" rid="bph13364-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="author-note" rid="bph13364-note-0001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0004">
<name>
<surname>Di Biase</surname>
<given-names>M A</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7100-651X</contrib-id>
<xref ref-type="aff" rid="bph13364-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="author-note" rid="bph13364-note-0001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0005">
<name>
<surname>Everall</surname>
<given-names>I</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3957-3861</contrib-id>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0006">
<name>
<surname>Chana</surname>
<given-names>G</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1096-1986</contrib-id>
<xref ref-type="aff" rid="bph13364-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0007">
<name>
<surname>Christopoulos</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="bph13364-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0008">
<name>
<surname>Skafidas</surname>
<given-names>E</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4263-9972</contrib-id>
<xref ref-type="aff" rid="bph13364-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0009">
<name>
<surname>Cropley</surname>
<given-names>V L</given-names>
</name>
<xref ref-type="aff" rid="bph13364-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="author-note" rid="bph13364-note-0002">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13364-cr-0010">
<name>
<surname>Pantelis</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="bph13364-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="bph13364-aff-0004">
<sup>4</sup>
</xref>
<xref ref-type="author-note" rid="bph13364-note-0002">
<sup>†</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph13364-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Melbourne Neuropsychiatry Centre, Department of Psychiatry</named-content>
<institution>The University of Melbourne and Melbourne Health</institution>
<named-content content-type="city">Carlton South</named-content>
<named-content content-type="country-part">VIC</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="bph13364-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Centre for Neural Engineering</named-content>
<institution>The University of Melbourne</institution>
<named-content content-type="city">Carlton</named-content>
<named-content content-type="country-part">VIC</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="bph13364-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>The University of Melbourne</institution>
<named-content content-type="city">Parkville</named-content>
<named-content content-type="country-part">VIC</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="bph13364-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Florey Institute for Neurosciences and Mental Health</institution>
<named-content content-type="city">Parkville</named-content>
<named-content content-type="country-part">VIC</named-content>
<country country="AU">Australia</country>
</aff>
<aff id="bph13364-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences</named-content>
<institution>Monash University</institution>
<named-content content-type="city">Parkville</named-content>
<named-content content-type="country-part">VIC</named-content>
<country country="AU">Australia</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Liliana Laskaris, Maria Di Biase and Professor Christos Pantelis, Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne Carlton South, VIC, Australia. E‐mail: <email>lilianal@student.unimelb.edu.au</email>; <email>dibiasem@unimelb.edu.au</email>; <email>cpant@unimelb.edu.au</email><break></break></corresp>
<fn id="bph13364-note-0001">
<label>*</label>
<p>
Author equally contributed (joint first)</p>
</fn>
<fn id="bph13364-note-0002">
<label>†</label>
<p>
Author equally contributed (joint senior)</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2016</year>
</pub-date>
<volume>173</volume>
<issue>4</issue>
<issue-id pub-id-type="doi">10.1111/bph.v173.4</issue-id>
<issue-title content-type="special-issue-title">Themed Section: Inflammation: Maladies, Models, Mechanisms and Molecules</issue-title>
<fpage>666</fpage>
<lpage>680</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>8</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2015 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-173-666.pdf" xlink:type="simple"></self-uri>
<abstract abstract-type="main">
<sec id="bph13364-sec-2002">
<p>Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.</p>
</sec>
<sec id="bph13364-sec-1002">
<title>Linked Articles</title>
<p>This article is part of a themed section on Inflammation: maladies, models, mechanisms and molecules. To view the other articles in this section visit <ext-link ext-link-type="uri" xlink:href="10.1111/bph.2016.173.issue-4">http://dx.doi.org/10.1111/bph.2016.173.issue-4</ext-link>
</p>
</sec>
</abstract>
<counts>
<page-count count="15"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph13364</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>February 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:04.02.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph13364-cit-0000" publication-type="journal">
<string-name>
<surname>Laskaris</surname>, <given-names>L. E.</given-names>
</string-name>, <string-name>
<surname>Di Biase</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Everall</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Chana</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Christopoulos</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Skafidas</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Cropley</surname>, <given-names>V. L.</given-names>
</string-name>, and <string-name>
<surname>Pantelis</surname>, <given-names>C.</given-names>
</string-name> (<year>2016</year>) <article-title>Microglial activation and progressive brain changes in schizophrenia</article-title>. <source/>British Journal of Pharmacology, <volume>173</volume>: <fpage>666</fpage>–<lpage>680</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bph.13364">10.1111/bph.13364</ext-link>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>